Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.18 USD

41.18
3,160,813

+0.86 (2.13%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $41.19 +0.01 (0.02%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Top Ranked Income Stocks to Buy for February 14th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, February 14th

Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

by Zacks Equity Research

Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

by Zacks Equity Research

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

by Zacks Equity Research

Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge

Mark Vickery headshot

Big Q4 Numbers & New Trade Data

by Mark Vickery

Plenty of Q4 earnings numbers join new Manufacturing and Trade data, some of which had been previously delayed due to the government shutdown.

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q4

by Zacks Equity Research

Glaxo beats both earnings and sales estimates in the fourth quarter of 2018.

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

by Zacks Equity Research

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

What's in the Cards for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.

Mylan's Generic Version of Advair Diskus Wins FDA Approval

by Zacks Equity Research

Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

GlaxoSmithKline (GSK) Flat As Market Gains: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.

Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines

by Zacks Equity Research

Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.

Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status

by Zacks Equity Research

Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.

Pfizer (PFE) Q4 Earnings Beat, 2019 View Tepid, Stock Dips

by Zacks Equity Research

Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.

Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe

by Zacks Equity Research

Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

by Sanghamitra Saha

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Why Should You Hold Genpact (G) Stock in Your Portfolio?

by Zacks Equity Research

Strong domain expertise in business analytics, digital and consulting services to boost demand for Genpact's (G) offerings.

Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

by Zacks Equity Research

Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

New Strong Sell Stocks for January 11th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Kinjel Shah headshot

4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

by Kinjel Shah

Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting

by Zacks Equity Research

Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.